Portola’s approach to Lovenox reversal is not materially different from PYMX’s. Both companies’ compounds block LMWHs such as Lovenox from binding to antithrombin, which makes LMWH unable to inhibit FXa. Please see #msg-26898084 for a pictorial on the interaction of LMWH and antithrombin (shown as ATIII).
Market Data 
Markets 
AI
